Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)
This study has been terminated.
Sponsor:
Schering-Plough
Information provided by:
Schering-Plough
ClinicalTrials.gov Identifier:
NCT00040534
First received: June 28, 2002
Last updated: May 31, 2006
Last verified: May 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with Gemcitabine and Cisplatin in patients with advanced cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Neoplasms |
Drug: Farnesyl Protein Transferase Inhibitor |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Schering-Plough:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Advanced cancer for which there is no treatment available which would have a reasonable chance of disease palliation or cure
- Age greater than or equal to 18.
- SWOG performance Status less than or equal to 2.
- Meets protocol requirements for specified laboratory values.
- Written informed consent and cooperation of patient.
Exclusion Criteria:
- Prior treatment with an FPTI
- Knowledge of intracranial metastases or carcinomatous meningitis.
- Poor medical risks because of nonmalignant systemic disease or uncontrolled active infection.
- Medical conditions that would interfere with taking oral medications.
- Significant uncontrolled diarrhea.
- Chemotherapy, radiotherapy or major surgery within 4 weeks; full recovery from prior treatment.
- Concomitant use of CYP3A inhibitors/inducers per protocol.
- Known HIV positivity or AIDS-related illness.
- Pregnant or nursing women.
- Men or women of childbearing potential who are not using an effective method of contraception.
- Concurrent chemotherapy, hormonal therapy, radiotherapy or immunotherapy.
- QTc prolongation (>440 msecs) at baseline.
- Patients with previous high-dose therapy requiring stem cell rescue or bone marrow transplant, or irradiation to >30% of bone marrow-containing areas.
- Patients that have received Mitomycin-C or nitrosoureas.
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00040534 History of Changes |
| Other Study ID Numbers: | P01499 |
| Study First Received: | June 28, 2002 |
| Last Updated: | May 31, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Schering-Plough:
|
Advanced Cancer |
Additional relevant MeSH terms:
|
Neoplasms |
ClinicalTrials.gov processed this record on June 18, 2013